127 related articles for article (PubMed ID: 38488343)
21. Prostate-specific antigen (PSA) concentrations in hypogonadal men during 6 years of transdermal testosterone treatment.
Raynaud JP; Gardette J; Rollet J; Legros JJ
BJU Int; 2013 May; 111(6):880-90. PubMed ID: 23294726
[TBL] [Abstract][Full Text] [Related]
22. Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis.
Zhu J; Zhang W; Ou N; Song Y; Kang J; Liang Z; Hu R; Yang Y; Liu X
Transl Androl Urol; 2020 Apr; 9(2):591-600. PubMed ID: 32420164
[TBL] [Abstract][Full Text] [Related]
23. Waist circumference is superior to weight and BMI in predicting sexual symptoms, voiding symptoms and psychosomatic symptoms in men with hypogonadism and erectile dysfunction.
Yassin AA; Nettleship JE; Salman M; Almehmadi Y
Andrologia; 2017 May; 49(4):. PubMed ID: 27400881
[TBL] [Abstract][Full Text] [Related]
24. Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study.
Yassin A; Haider A; Haider KS; Caliber M; Doros G; Saad F; Garvey WT
Diabetes Care; 2019 Jun; 42(6):1104-1111. PubMed ID: 30862651
[TBL] [Abstract][Full Text] [Related]
25. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life.
Yassin DJ; Doros G; Hammerer PG; Yassin AA
J Sex Med; 2014 Jun; 11(6):1567-76. PubMed ID: 24712761
[TBL] [Abstract][Full Text] [Related]
26. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
[TBL] [Abstract][Full Text] [Related]
27. Adding liraglutide to lifestyle changes, metformin and testosterone therapy boosts erectile function in diabetic obese men with overt hypogonadism.
Giagulli VA; Carbone MD; Ramunni MI; Licchelli B; De Pergola G; Sabbà C; Guastamacchia E; Triggiani V
Andrology; 2015 Nov; 3(6):1094-103. PubMed ID: 26447645
[TBL] [Abstract][Full Text] [Related]
28. Testosterone replacement therapy does not promote priapism in hypogonadal men with sickle cell disease: 12-month safety report.
Morrison BF; Reid M; Madden W; Burnett AL
Andrology; 2013 Jul; 1(4):576-82. PubMed ID: 23606509
[TBL] [Abstract][Full Text] [Related]
29. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.
Arver S; Dobs AS; Meikle AW; Caramelli KE; Rajaram L; Sanders SW; Mazer NA
Clin Endocrinol (Oxf); 1997 Dec; 47(6):727-37. PubMed ID: 9497881
[TBL] [Abstract][Full Text] [Related]
30. Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes.
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P
J Sex Med; 2013 Jun; 10(6):1612-27. PubMed ID: 23551886
[TBL] [Abstract][Full Text] [Related]
31. Topical Testosterone Therapy Adherence and Outcomes Among Men With Primary or Secondary Hypogonadism.
Grabner M; Hepp Z; Raval A; Tian F; Khera M
J Sex Med; 2018 Feb; 15(2):148-158. PubMed ID: 29425664
[TBL] [Abstract][Full Text] [Related]
32. Testosterone Therapy and Risk of Acute Myocardial Infarction in Hypogonadal Men: An Administrative Health Care Claims Study.
Li H; Mitchell L; Zhang X; Heiselman D; Motsko S
J Sex Med; 2017 Nov; 14(11):1307-1317. PubMed ID: 29110802
[TBL] [Abstract][Full Text] [Related]
33. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.
Debruyne FM; Behre HM; Roehrborn CG; Maggi M; Wu FC; Schröder FH; Jones TH; Porst H; Hackett G; Wheaton OA; Martin-Morales A; Meuleman E; Cunningham GR; Divan HA; Rosen RC;
BJU Int; 2017 Feb; 119(2):216-224. PubMed ID: 27409523
[TBL] [Abstract][Full Text] [Related]
34. Effects of continuous long-term testosterone therapy (TTh) on anthropometric, endocrine and metabolic parameters for up to 10 years in 115 hypogonadal elderly men: real-life experience from an observational registry study.
Yassin AA; Nettleship J; Almehmadi Y; Salman M; Saad F
Andrologia; 2016 Sep; 48(7):793-9. PubMed ID: 26762680
[TBL] [Abstract][Full Text] [Related]
35. Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism.
Okada K; Miyake H; Ishida T; Sumii K; Enatsu N; Chiba K; Matsushita K; Fujisawa M
Am J Mens Health; 2018 Sep; 12(5):1403-1408. PubMed ID: 27256990
[TBL] [Abstract][Full Text] [Related]
36. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men.
Zitzmann M; Mattern A; Hanisch J; Gooren L; Jones H; Maggi M
J Sex Med; 2013 Feb; 10(2):579-88. PubMed ID: 22812645
[TBL] [Abstract][Full Text] [Related]
37. Metabolic phenotype of male obesity-related secondary hypogonadism pre-replacement and post-replacement therapy with intra-muscular testosterone undecanoate therapy.
Dimitriadis GK; Randeva HS; Aftab S; Ali A; Hattersley JG; Pandey S; Grammatopoulos DK; Valsamakis G; Mastorakos G; Jones TH; Barber TM
Endocrine; 2018 Apr; 60(1):175-184. PubMed ID: 29396841
[TBL] [Abstract][Full Text] [Related]
38. Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study.
Haider KS; Haider A; Saad F; Doros G; Hanefeld M; Dhindsa S; Dandona P; Traish A
Diabetes Obes Metab; 2020 Nov; 22(11):2055-2068. PubMed ID: 32558149
[TBL] [Abstract][Full Text] [Related]
39. Could Testosterone Replacement Therapy in Hypogonadal Men Ameliorate Anemia, a Cardiovascular Risk Factor? An Observational, 54-Week Cumulative Registry Study.
Zhang LT; Shin YS; Kim JY; Park JK
J Urol; 2016 Apr; 195(4 Pt 1):1057-64. PubMed ID: 26519655
[TBL] [Abstract][Full Text] [Related]
40. The response to testosterone undecanoate in men with type 2 diabetes is dependent on achieving threshold serum levels (the BLAST study).
Hackett G; Cole N; Bhartia M; Kennedy D; Raju J; Wilkinson P; Saghir A;
Int J Clin Pract; 2014 Feb; 68(2):203-15. PubMed ID: 24355040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]